e10vq
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 10-Q
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
FOR THE QUARTERLY PERIOD ENDED JUNE 30, 2005
Commission
File Number 001-16407
ZIMMER HOLDINGS, INC.
(Exact name of registrant as specified in its charter)
|
|
|
Delaware
(State or other jurisdiction of
incorporation or organization)
|
|
13-4151777
(IRS Employer Identification No.) |
345 East Main Street, Warsaw, IN 46580
(Address of principal executive offices)
Telephone: (574) 267-6131
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by
Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for
such shorter period that the registrant was required to file such reports), and (2) has been
subject to such filing requirements for the past 90 days. Yes þ No o
Indicate by checkmark whether the registrant is an accelerated filer (as defined in Rule 12b-2 of
the Act). Yes þ No o
At July 29, 2005, there were 247,343,674 shares outstanding of the registrants $.01 par value
Common Stock.
ZIMMER HOLDINGS, INC.
INDEX TO FORM 10-Q
June 30, 2005
2
Part I Financial Information
Item 1. Financial Statements
ZIMMER HOLDINGS, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF EARNINGS
(in millions, except per share amounts, unaudited)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended June 30, |
|
Six Months Ended June 30, |
|
|
2005 |
|
2004 |
|
2005 |
|
2004 |
Net Sales |
|
$ |
846.8 |
|
|
$ |
737.4 |
|
|
$ |
1,675.3 |
|
|
$ |
1,479.6 |
|
Cost of products sold |
|
|
188.8 |
|
|
|
201.9 |
|
|
|
379.1 |
|
|
|
421.4 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Gross Profit |
|
|
658.0 |
|
|
|
535.5 |
|
|
|
1,296.2 |
|
|
|
1,058.2 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Research and development |
|
|
43.6 |
|
|
|
38.2 |
|
|
|
85.7 |
|
|
|
78.0 |
|
Selling, general and administrative |
|
|
328.5 |
|
|
|
297.3 |
|
|
|
650.1 |
|
|
|
595.1 |
|
Acquisition and integration |
|
|
10.1 |
|
|
|
24.2 |
|
|
|
27.0 |
|
|
|
55.5 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Operating expenses |
|
|
382.2 |
|
|
|
359.7 |
|
|
|
762.8 |
|
|
|
728.6 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Operating Profit |
|
|
275.8 |
|
|
|
175.8 |
|
|
|
533.4 |
|
|
|
329.6 |
|
Interest expense |
|
|
4.2 |
|
|
|
8.3 |
|
|
|
11.4 |
|
|
|
18.1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Earnings before income taxes and minority interest |
|
|
271.6 |
|
|
|
167.5 |
|
|
|
522.0 |
|
|
|
311.5 |
|
Provision for income taxes |
|
|
80.7 |
|
|
|
51.4 |
|
|
|
157.3 |
|
|
|
97.8 |
|
Minority interest |
|
|
(0.2 |
) |
|
|
0.2 |
|
|
|
(0.4 |
) |
|
|
0.2 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net Earnings |
|
$ |
190.7 |
|
|
$ |
116.3 |
|
|
$ |
364.3 |
|
|
$ |
213.9 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Earnings Per Common Share |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Basic |
|
$ |
0.77 |
|
|
$ |
0.48 |
|
|
$ |
1.48 |
|
|
$ |
0.88 |
|
Diluted |
|
$ |
0.76 |
|
|
$ |
0.47 |
|
|
$ |
1.46 |
|
|
$ |
0.87 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted Average Common Shares Outstanding |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Basic |
|
|
247.0 |
|
|
|
244.3 |
|
|
|
246.5 |
|
|
|
243.6 |
|
Diluted |
|
|
249.9 |
|
|
|
247.9 |
|
|
|
249.5 |
|
|
|
247.2 |
|
The accompanying notes are an integral part of these consolidated financial statements.
3
ZIMMER HOLDINGS, INC. AND SUBSIDIARIES
CONSOLIDATED BALANCE SHEETS
(in millions, except share amounts)
|
|
|
|
|
|
|
|
|
|
|
June 30, |
|
December 31 |
|
|
2005 |
|
2004 |
|
|
(unaudited) |
|
|
|
|
ASSETS: |
|
|
|
|
|
|
|
|
Current Assets: |
|
|
|
|
|
|
|
|
Cash and equivalents |
|
$ |
78.8 |
|
|
$ |
154.6 |
|
Restricted cash |
|
|
16.6 |
|
|
|
18.9 |
|
Accounts receivable, less allowance for doubtful accounts |
|
|
573.4 |
|
|
|
524.8 |
|
Inventories, net |
|
|
568.0 |
|
|
|
536.0 |
|
Prepaid expenses |
|
|
43.2 |
|
|
|
54.0 |
|
Deferred income taxes |
|
|
212.2 |
|
|
|
272.6 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total current assets |
|
|
1,492.2 |
|
|
|
1,560.9 |
|
|
|
|
|
|
|
|
|
|
Property, plant and equipment, net |
|
|
676.6 |
|
|
|
628.5 |
|
Goodwill |
|
|
2,434.2 |
|
|
|
2,528.9 |
|
Intangible assets, net |
|
|
779.1 |
|
|
|
794.8 |
|
Other assets |
|
|
169.4 |
|
|
|
182.4 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total Assets |
|
$ |
5,551.5 |
|
|
$ |
5,695.5 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
LIABILITIES AND STOCKHOLDERS EQUITY |
|
|
|
|
|
|
|
|
Current Liabilities: |
|
|
|
|
|
|
|
|
Accounts payable |
|
$ |
141.8 |
|
|
$ |
131.6 |
|
Income taxes payable |
|
|
16.9 |
|
|
|
34.2 |
|
Fair value of derivatives |
|
|
17.2 |
|
|
|
72.8 |
|
Other current liabilities |
|
|
438.0 |
|
|
|
434.9 |
|
Short-term debt |
|
|
|
|
|
|
27.5 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total current liabilities |
|
|
613.9 |
|
|
|
701.0 |
|
|
|
|
|
|
|
|
|
|
Other long-term liabilities |
|
|
363.1 |
|
|
|
420.9 |
|
Long-term debt |
|
|
268.1 |
|
|
|
624.0 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total Liabilities |
|
|
1,245.1 |
|
|
|
1,745.9 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Commitments and Contingencies (Note 12) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Minority interest |
|
|
1.8 |
|
|
|
7.1 |
|
|
|
|
|
|
|
|
|
|
Stockholders Equity: |
|
|
|
|
|
|
|
|
Common stock, $.01 par value, one billion shares authorized,
247.2 million in 2005 (245.5 million in 2004) issued and
outstanding |
|
|
2.5 |
|
|
|
2.5 |
|
Paid-in capital |
|
|
2,569.9 |
|
|
|
2,485.2 |
|
|
Retained earnings |
|
|
1,565.8 |
|
|
|
1,201.5 |
|
|
Accumulated other comprehensive income |
|
|
166.4 |
|
|
|
253.3 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total Stockholders Equity |
|
|
4,304.6 |
|
|
|
3,942.5 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total Liabilities and Stockholders Equity |
|
$ |
5,551.5 |
|
|
$ |
5,695.5 |
|
|
|
|
|
|
|
|
|
|
The accompanying notes are an integral part of these consolidated financial statements.
4
ZIMMER HOLDINGS, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF CASH FLOWS
(in millions, unaudited)
|
|
|
|
|
|
|
|
|
|
|
For the Six Months |
|
|
Ended June 30, |
|
|
2005 |
|
2004 |
Cash flows provided by (used in) operating activities: |
|
|
|
|
|
|
|
|
Net earnings |
|
$ |
364.3 |
|
|
$ |
213.9 |
|
Adjustments to reconcile net earnings to cash provided
by operating activities: |
|
|
|
|
|
|
|
|
Depreciation and amortization |
|
|
90.4 |
|
|
|
87.3 |
|
Inventory step-up |
|
|
4.1 |
|
|
|
49.6 |
|
Changes in operating assets and liabilities, net of acquisitions: |
|
|
|
|
|
|
|
|
Income taxes |
|
|
79.9 |
|
|
|
93.6 |
|
Receivables |
|
|
(66.6 |
) |
|
|
(44.2 |
) |
Inventories |
|
|
(58.6 |
) |
|
|
(14.3 |
) |
Accounts payable and accrued expenses |
|
|
(1.1 |
) |
|
|
(27.0 |
) |
Other assets and liabilities |
|
|
(16.3 |
) |
|
|
39.4 |
|
|
|
|
|
|
|
|
|
|
Net cash provided by operating activities |
|
|
396.1 |
|
|
|
398.3 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cash flows provided by (used in) investing activities: |
|
|
|
|
|
|
|
|
Additions to instruments |
|
|
(90.6 |
) |
|
|
(74.9 |
) |
Additions to other property, plant and equipment |
|
|
(42.2 |
) |
|
|
(30.6 |
) |
Centerpulse and InCentive acquisitions, net of acquired cash |
|
|
|
|
|
|
(18.2 |
) |
Implex acquisition, net of acquired cash |
|
|
|
|
|
|
(103.7 |
) |
Proceeds from note receivable |
|
|
|
|
|
|
25.0 |
|
Investments in other assets |
|
|
(9.7 |
) |
|
|
(1.1 |
) |
|
|
|
|
|
|
|
|
|
Net cash used in investing activities |
|
|
(142.5 |
) |
|
|
(203.5 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cash flows provided by (used in) financing activities: |
|
|
|
|
|
|
|
|
Net proceeds (payments) on lines of credit |
|
|
174.7 |
|
|
|
(239.4 |
) |
Payments on term loan |
|
|
(550.0 |
) |
|
|
|
|
Proceeds from exercise of stock options |
|
|
52.1 |
|
|
|
49.7 |
|
Debt issuance costs |
|
|
(1.9 |
) |
|
|
|
|
Equity issuance costs |
|
|
|
|
|
|
(5.0 |
) |
|
|
|
|
|
|
|
|
|
Net cash used in financing activities |
|
|
(325.1 |
) |
|
|
(194.7 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Effect of exchange rates on cash and equivalents |
|
|
(4.3 |
) |
|
|
(0.7 |
) |
|
|
|
|
|
|
|
|
|
Decrease in cash and equivalents |
|
|
(75.8 |
) |
|
|
(0.6 |
) |
|
|
|
|
|
|
|
|
|
Cash and equivalents, beginning of year |
|
|
154.6 |
|
|
|
77.5 |
|
|
|
|
|
|
|
|
|
|
Cash and equivalents, end of period |
|
$ |
78.8 |
|
|
$ |
76.9 |
|
|
|
|
|
|
|
|
|
|
The accompanying notes are an integral part of these consolidated financial statements.
5
ZIMMER HOLDINGS, INC. AND SUBSIDIARIES
NOTES TO INTERIM CONSOLIDATED FINANCIAL STATEMENTS
1. Basis of Presentation
The financial data presented herein is unaudited and should be read in conjunction with the
consolidated financial statements and accompanying notes included in the 2004 annual report on Form
10-K filed by Zimmer Holdings, Inc. (together with all its subsidiaries, the Company). In the
opinion of management, the accompanying unaudited consolidated financial statements include all
adjustments necessary for a fair statement of the financial position, results of operations and
cash flows for the interim periods presented. Results for interim periods should not be considered
indicative of results for the full year. Certain amounts in the three and six month periods ended
June 30, 2004 have been reclassified to conform to the current year presentation.
2. Stock Compensation
At June 30, 2005, the Company had three stock-based compensation plans for employees and
non-employee directors, which are described more fully in the notes to the consolidated financial
statements included in the Companys 2004 annual report on Form 10-K, an employee stock purchase
plan and a restricted stock plan for certain key members of management. The Company accounts for
those plans under the recognition and measurement principles of APB Opinion No. 25, Accounting for
Stock Issued to Employees, and related Interpretations. For stock options that vest based upon
service, no share-based compensation cost is reflected in net earnings, as the options granted
under the plans had exercise prices equal to the market value of the underlying common stock on the
date of grant. The Company also has performance-conditioned stock options issued in 2005 that
require the Company to recognize an expense to the extent the market value of the stock exceeds the
stock option exercise price on the measurement date. However, no compensation cost was recognized
in the three and six month periods ended June 30, 2005, as the stock option exercise price exceeded
the market value of the stock. No compensation cost is reflected in net income for the employee
stock purchase plan under the provisions of APB 25, which allows a discounted purchase price under
Section 423 of the Internal Revenue Code. Compensation cost related to restricted stock is
recognized in earnings over the vesting period of the stock, which is generally five years.
Compensation cost related to restricted stock was not significant for the three and six month
periods ended June 30, 2005 and 2004. The following table illustrates the effect on net earnings
and earnings per share if the Company had applied the fair value recognition provisions of
Statement of Financial Accounting Standards (SFAS) No. 123, Accounting for Stock Based
Compensation, to the above plans.
6
(in millions, except per share amounts)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months |
|
Six Months |
|
|
Ended June 30, |
|
Ended June 30, |
|
|
2005 |
|
2004 |
|
2005 |
|
2004 |
Net earnings, as reported |
|
$ |
190.7 |
|
|
$ |
116.3 |
|
|
$ |
364.3 |
|
|
$ |
213.9 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Deduct: Total stock-based compensation
expense determined under fair value
based method for all awards, net of tax |
|
|
(10.8 |
) |
|
|
(5.3 |
) |
|
|
(25.8 |
) |
|
|
(10.7 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Pro forma net earnings |
|
$ |
179.9 |
|
|
$ |
111.0 |
|
|
$ |
338.5 |
|
|
$ |
203.2 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Earnings per share: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Basic as reported |
|
$ |
0.77 |
|
|
$ |
0.48 |
|
|
$ |
1.48 |
|
|
$ |
0.88 |
|
Basic pro forma |
|
|
0.73 |
|
|
|
0.45 |
|
|
|
1.37 |
|
|
|
0.83 |
|
Diluted as reported |
|
|
0.76 |
|
|
|
0.47 |
|
|
|
1.46 |
|
|
|
0.87 |
|
Diluted pro forma |
|
|
0.72 |
|
|
|
0.45 |
|
|
|
1.36 |
|
|
|
0.82 |
|
In December 2004, the FASB issued SFAS No. 123(R), Share-Based Payment, which is a revision
to SFAS No. 123, Accounting for Stock Based Compensation. SFAS 123(R) requires all share-based
payments to employees, including stock options, to be expensed based on their fair values. The
Company has disclosed the effect on net earnings and earnings per share if the Company had applied
the fair value recognition provisions of SFAS 123. SFAS 123(R) contains three methodologies for
adoption: 1) adopt SFAS 123(R) on the effective date for interim periods thereafter, 2) adopt SFAS
123(R) on the effective date for interim periods thereafter and restate prior interim periods
included in the fiscal year of adoption under the provisions of SFAS 123, or 3) adopt SFAS 123(R)
on the effective date for interim periods thereafter and restate all prior interim periods under
the provisions of SFAS 123. The SEC has amended the compliance dates of SFAS 123(R) requiring
adoption in the first fiscal year beginning after June 15, 2005. The Company intends to adopt SFAS
123(R) on January 1, 2006.
3. Inventories
|
|
|
|
|
|
|
|
|
|
|
June 30, |
|
December 31, |
|
|
2005 |
|
2004 |
|
|
(in millions) |
Finished goods |
|
$ |
428.8 |
|
|
$ |
420.5 |
|
Work in progress |
|
|
51.1 |
|
|
|
42.0 |
|
Raw materials |
|
|
87.1 |
|
|
|
70.2 |
|
Inventory step-up (primarily finished goods) |
|
|
1.0 |
|
|
|
3.3 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Inventories, net |
|
$ |
568.0 |
|
|
$ |
536.0 |
|
|
|
|
|
|
|
|
|
|
7
4. Property, Plant and Equipment
|
|
|
|
|
|
|
|
|
|
|
June 30, |
|
December 31, |
|
|
2005 |
|
2004 |
|
|
(in millions) |
Land |
|
$ |
19.9 |
|
|
$ |
20.0 |
|
Buildings and equipment |
|
|
684.9 |
|
|
|
677.1 |
|
Instruments |
|
|
616.5 |
|
|
|
557.8 |
|
Construction in progress |
|
|
57.5 |
|
|
|
57.9 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1,378.8 |
|
|
|
1,312.8 |
|
Accumulated depreciation |
|
|
(702.2 |
) |
|
|
(684.3 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Property, plant and equipment, net |
|
$ |
676.6 |
|
|
$ |
628.5 |
|
|
|
|
|
|
|
|
|
|
5. Goodwill and Other Intangible Assets
The following table summarizes the changes in the carrying amount of goodwill for the six
month period ended June 30, 2005 (in millions):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Americas |
|
Europe |
|
Asia Pacific |
|
Total |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance at January 1, 2005 |
|
$ |
1,389.1 |
|
|
$ |
1,023.2 |
|
|
$ |
116.6 |
|
|
$ |
2,528.9 |
|
Change in preliminary fair value
estimates of Centerpulse related to: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Integration liability |
|
|
(0.2 |
) |
|
|
(1.4 |
) |
|
|
|
|
|
|
(1.6 |
) |
Income taxes |
|
|
0.2 |
|
|
|
0.5 |
|
|
|
|
|
|
|
0.7 |
|
Implex earn-out liability |
|
|
14.5 |
|
|
|
|
|
|
|
|
|
|
|
14.5 |
|
Change in preliminary fair value
estimates of Implex |
|
|
0.2 |
|
|
|
|
|
|
|
|
|
|
|
0.2 |
|
Purchase of Allo Systems Srl
minority interest |
|
|
|
|
|
|
2.1 |
|
|
|
|
|
|
|
2.1 |
|
Currency translation |
|
|
|
|
|
|
(107.3 |
) |
|
|
(3.3 |
) |
|
|
(110.6 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance at June 30, 2005 |
|
$ |
1,403.8 |
|
|
$ |
917.1 |
|
|
$ |
113.3 |
|
|
$ |
2,434.2 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
8
The components of identifiable intangible assets are as follows (in millions):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Trademarks |
|
|
|
|
|
|
|
|
Core |
|
Developed |
|
and Trade |
|
Customer |
|
|
|
|
|
|
Technology |
|
Technology |
|
Names |
|
Relationships |
|
Other |
|
Total |
As of June 30, 2005: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Intangible assets subject to
amortization: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Gross carrying amount |
|
$ |
117.9 |
|
|
$ |
417.3 |
|
|
$ |
31.7 |
|
|
$ |
34.4 |
|
|
$ |
39.5 |
|
|
$ |
640.8 |
|
Accumulated amortization |
|
|
(11.0 |
) |
|
|
(45.9 |
) |
|
|
(5.3 |
) |
|
|
(2.0 |
) |
|
|
(15.2 |
) |
|
|
(79.4 |
) |
Intangible assets not subject to amortization: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Gross carrying amount |
|
|
|
|
|
|
|
|
|
|
217.7 |
|
|
|
|
|
|
|
|
|
|
|
217.7 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total identifiable intangible assets |
|
$ |
106.9 |
|
|
$ |
371.4 |
|
|
$ |
244.1 |
|
|
$ |
32.4 |
|
|
$ |
24.3 |
|
|
$ |
779.1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
As of December 31, 2004: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Intangible assets subject to
amortization: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Gross carrying amount |
|
$ |
117.9 |
|
|
$ |
417.3 |
|
|
$ |
31.7 |
|
|
$ |
34.4 |
|
|
$ |
34.1 |
|
|
$ |
635.4 |
|
Accumulated amortization |
|
|
(8.0 |
) |
|
|
(31.9 |
) |
|
|
(3.8 |
) |
|
|
(1.3 |
) |
|
|
(13.7 |
) |
|
|
(58.7 |
) |
Intangible assets not subject to amortization: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Gross carrying amount |
|
|
|
|
|
|
|
|
|
|
218.1 |
|
|
|
|
|
|
|
|
|
|
|
218.1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total identifiable intangible assets |
|
$ |
109.9 |
|
|
$ |
385.4 |
|
|
$ |
246.0 |
|
|
$ |
33.1 |
|
|
$ |
20.4 |
|
|
$ |
794.8 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Amortization expense for the three and six month periods ended June 30, 2005 was $10.4
million and $20.7 million, respectively. Amortization expense for the three and six month periods
ended June 30, 2004 was $9.9 million and $18.5 million, respectively. Amortization expense was
recorded as part of selling, general and administrative.
6. Integration Liability
On October 2, 2003 (the Closing Date), the Company closed its exchange offer for Centerpulse
AG (Centerpulse), a global orthopaedic medical device company headquartered in Switzerland that
services the reconstructive joint, spine and dental implant markets. As of the Closing Date, the
Company recorded a $75.7 million integration liability consisting of $53.1 million of employee
termination and relocation costs and $22.6 million of sales agent and lease contract termination
costs. In accordance with EITF 95-3 Recognition of Liabilities Assumed in a Purchase Business
Combination, these liabilities were included in the allocation of the purchase price. Increases
to the liability subsequent to the completion of the allocation period were expensed in the
financial statements, and were not significant. Reductions in the liability subsequent to the
completion of the allocation period were recorded as adjustments to goodwill.
The Companys integration plan covers all functional business areas, including sales force,
research and development, manufacturing and administrative. Approximately 830 Centerpulse
employees have been or will be involuntarily terminated through the Companys integration
plan. The Company began phasing-out production at its Austin, Texas manufacturing facility in
2004. The phase out will result in the involuntary termination of approximately 550 employees,
including 390 employees involved in manufacturing. Products previously manufactured at the
9
Austin
facility will be sourced from the Companys other manufacturing facilities. The Company has begun
to hire additional manufacturing employees at its other manufacturing facilities to handle
increased production schedules. The Austin phase out is expected to be completed in late 2005. As
of June 30, 2005, approximately 540 Centerpulse employees had been involuntarily terminated. With
a few exceptions, the Companys integration plan is expected to be completed by the end of 2005.
Reconciliation of the integration liability, as of June 30, 2005, is as follows (in millions):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Employee |
|
|
|
|
|
|
Termination |
|
|
|
|
|
|
and Relocation |
|
Contract |
|
|
|
|
Costs |
|
Terminations |
|
Total |
Balance, Closing Date |
|
$ |
53.1 |
|
|
$ |
22.6 |
|
|
$ |
75.7 |
|
Cash Payments |
|
|
(20.7 |
) |
|
|
(0.2 |
) |
|
|
(20.9 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance, December 31, 2003 |
|
|
32.4 |
|
|
|
22.4 |
|
|
|
54.8 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cash Payments |
|
|
(20.5 |
) |
|
|
(2.3 |
) |
|
|
(22.8 |
) |
Additions/(Reductions), net |
|
|
3.7 |
|
|
|
(11.8 |
) |
|
|
(8.1 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance, December 31, 2004 |
|
|
15.6 |
|
|
|
8.3 |
|
|
|
23.9 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cash Payments |
|
|
(4.4 |
) |
|
|
(2.4 |
) |
|
|
(6.8 |
) |
Reductions |
|
|
(0.3 |
) |
|
|
(1.3 |
) |
|
|
(1.6 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance, June 30, 2005 |
|
$ |
10.9 |
|
|
$ |
4.6 |
|
|
$ |
15.5 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
7. Comprehensive Income
The reconciliation of net earnings to comprehensive income is as follows:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months |
|
Six Months |
|
|
Ended June 30, |
|
Ended June 30, |
|
|
2005 |
|
2004 |
|
2005 |
|
2004 |
|
|
(in millions) |
|
(in millions) |
Net Earnings |
|
$ |
190.7 |
|
|
$ |
116.3 |
|
|
$ |
364.3 |
|
|
$ |
213.9 |
|
Other Comprehensive Income (Loss): |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Foreign currency cumulative translation adjustments |
|
|
(97.8 |
) |
|
|
1.1 |
|
|
|
(152.3 |
) |
|
|
1.0 |
|
Unrealized foreign currency hedge gains, net of tax |
|
|
35.2 |
|
|
|
1.7 |
|
|
|
47.3 |
|
|
|
2.9 |
|
Reclassification adjustments on foreign currency
hedges, net of tax |
|
|
11.9 |
|
|
|
4.9 |
|
|
|
19.5 |
|
|
|
8.0 |
|
Unrealized gains (losses) on securities, net of tax |
|
|
0.1 |
|
|
|
|
|
|
|
(1.4 |
) |
|
|
|
|
Minimum pension liability, net of tax |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
0.6 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total Other Comprehensive Income (Loss) |
|
|
(50.6 |
) |
|
|
7.7 |
|
|
|
(86.9 |
) |
|
|
12.5 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Comprehensive Income |
|
$ |
140.1 |
|
|
$ |
124.0 |
|
|
$ |
277.4 |
|
|
$ |
226.4 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
10
8. Financial Instruments
The Company is exposed to market risk due to changes in currency exchange rates. As a result,
the Company utilizes foreign exchange forward contracts to offset the effect of exchange rate
fluctuations on certain anticipated foreign currency transactions, generally intercompany sales and
purchases expected to occur within the next twelve to twenty-four months. The Company does not hold
financial instruments for trading or speculative purposes. For derivatives which qualify as hedges
of future cash flows, the effective portion of changes in fair value is temporarily recorded in
other comprehensive income, then recognized in cost of products sold when the hedged item affects
earnings. The ineffective portion of a derivatives change in fair value, if any, is reported in
cost of products sold immediately. The net amount recognized in earnings during the three and six
month periods ended June 30, 2005 and 2004, due to ineffectiveness and amounts excluded from the
assessment of hedge effectiveness, was not significant. The fair value of outstanding derivative
instruments recorded on the balance sheet at June 30, 2005, together with settled derivatives where
the hedged item has not yet affected earnings, was a net unrealized loss of $14.7 million, or $6.6
million net of taxes, which is deferred in other comprehensive income, of which, $23.4 million, or
$14.6 million, net of taxes, is expected to be reclassified to earnings over the next twelve
months.
9. Retirement and Postretirement Benefit Plans
The Company has defined benefit pension plans covering certain U.S. and Puerto Rico employees
who were hired before September 2, 2002. Employees hired after September 2, 2002 are not part of
the U.S. and Puerto Rico defined benefit plans, but do receive additional benefits under the
Companys defined contribution plans. Plan benefits are primarily based on years of credited
service and the participants compensation. In addition to the U.S. and Puerto Rico defined
benefit pension plans, the Company sponsors various non-U.S. pension arrangements, including
retirement and termination benefit plans required by local law or coordinated with government
sponsored plans.
The Company also provides comprehensive medical and group life insurance benefits to certain
U.S. and Puerto Rico retirees who elect to participate in the Companys comprehensive medical and
group life plans. The medical plan is contributory, and the life insurance plan is
non-contributory. Employees hired after September 2, 2002 are not eligible for retiree medical and
life insurance benefits. No similar plans exist for employees outside the U.S. and Puerto Rico.
11
The components of net pension expense for the three and six month periods ended June 30, 2005
and 2004, for the Companys defined benefit retirement plans are as follows (in millions):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months |
|
Six Months |
|
|
Ended June 30, |
|
Ended June 30, |
|
|
2005 |
|
2004 |
|
2005 |
|
2004 |
Service cost |
|
$ |
5.0 |
|
|
$ |
5.7 |
|
|
$ |
10.2 |
|
|
$ |
11.5 |
|
Interest cost |
|
|
2.5 |
|
|
|
2.2 |
|
|
|
5.2 |
|
|
|
4.4 |
|
Expected return on plan assets |
|
|
(2.9 |
) |
|
|
(3.5 |
) |
|
|
(6.0 |
) |
|
|
(7.1 |
) |
Amortization of unrecognized actuarial loss |
|
|
0.6 |
|
|
|
0.4 |
|
|
|
1.2 |
|
|
|
0.8 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net periodic benefit cost |
|
$ |
5.2 |
|
|
$ |
4.8 |
|
|
$ |
10.6 |
|
|
$ |
9.6 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
The components of net periodic benefit expense for the three and six month periods ended June
30, 2005 and 2004, for the Companys postretirement benefit plans are as follows (in millions):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months |
|
Six Months |
|
|
Ended June 30, |
|
Ended June 30, |
|
|
2005 |
|
2004 |
|
2005 |
|
2004 |
Service cost |
|
$ |
0.4 |
|
|
$ |
0.4 |
|
|
$ |
0.8 |
|
|
$ |
0.8 |
|
Interest cost |
|
|
0.5 |
|
|
|
0.5 |
|
|
|
1.0 |
|
|
|
0.9 |
|
Amortization of unrecognized actuarial loss |
|
|
0.1 |
|
|
|
|
|
|
|
0.2 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net periodic benefit cost |
|
$ |
1.0 |
|
|
$ |
0.9 |
|
|
$ |
2.0 |
|
|
$ |
1.7 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
The Company contributed $9.2 million during the six month period ended June 30, 2005, to its
U.S. and Puerto Rico defined benefit plans and expects to contribute an additional $8 $10 million
to these plans during 2005. The Company contributed $4.3 million to its foreign based defined
benefit plans in the six month period ended June 30, 2005, and expects to contribute an additional
$4.8 million to these foreign based plans during 2005. Contributions for the U.S. and Puerto Rico
postretirement benefit plans are not expected to be significant.
10. Earnings Per Share
The following table reconciles the diluted shares used in computing diluted earnings per
share:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months |
|
Six Months |
|
|
Ended June 30, |
|
Ended June 30, |
|
|
2005 |
|
2004 |
|
2005 |
|
2004 |
|
|
(in millions) |
|
(in millions) |
Weighted average shares outstanding for
basic net earnings per share |
|
|
247.0 |
|
|
|
244.3 |
|
|
|
246.5 |
|
|
|
243.6 |
|
Effect of dilutive stock options |
|
|
2.9 |
|
|
|
3.6 |
|
|
|
3.0 |
|
|
|
3.6 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted average shares outstanding for
diluted net earnings per share |
|
|
249.9 |
|
|
|
247.9 |
|
|
|
249.5 |
|
|
|
247.2 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
12
At June 30, 2005 options to purchase 2.7 million shares of common stock were not included in the
computation of diluted earnings per share as the exercise prices of these options were greater than
the average market price of the common shares. There were no anti-dilutive securities outstanding
at June 30, 2004.
11. Segment Information
The Company designs, develops, manufactures and markets reconstructive orthopaedic implants,
including joint and dental, spinal implants, and trauma products and orthopaedic surgical products
which include surgical supplies and instruments designed to aid in orthopaedic surgical procedures.
Operations are managed through three major geographic segments the Americas, which is comprised
principally of the United States and includes other North, Central and South American markets;
Europe, which is comprised principally of Europe and includes the Middle East and Africa; and Asia
Pacific, which is comprised primarily of Japan and includes other Asian and Pacific markets. This
structure is the basis for the Companys reportable segment information discussed below. Company
management evaluates operating segment performance based upon segment operating profit exclusive of
operating expenses pertaining to global operations and corporate expenses, acquisition and
integration expenses, inventory step-up, in-process research and development write-offs and
intangible asset amortization expense. Global operations include research, development,
engineering, medical education, brand management, corporate legal, finance, human resource
functions, and U.S. and Puerto Rico based operations and logistics. Intercompany transactions have
been eliminated from segment operating profit.
Net sales and segment operating profit are as follows (in millions):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net Sales |
|
Operating Profit |
|
|
Three Months Ended |
|
Three Months Ended |
|
|
June 30, |
|
June 30, |
|
|
2005 |
|
2004 |
|
2005 |
|
2004 |
Americas |
|
$ |
494.7 |
|
|
$ |
432.2 |
|
|
$ |
258.8 |
|
|
$ |
226.1 |
|
Europe |
|
|
228.1 |
|
|
|
197.7 |
|
|
|
75.7 |
|
|
|
66.9 |
|
Asia Pacific |
|
|
124.0 |
|
|
|
107.5 |
|
|
|
54.8 |
|
|
|
44.8 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total |
|
$ |
846.8 |
|
|
$ |
737.4 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Inventory step-up |
|
|
|
|
|
|
|
|
|
|
(2.1 |
) |
|
|
(18.6 |
) |
Acquisition and integration |
|
|
|
|
|
|
|
|
|
|
(10.1 |
) |
|
|
(24.2 |
) |
Global operations and corporate functions |
|
|
|
|
|
|
|
|
|
|
(101.3 |
) |
|
|
(119.2 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Operating profit |
|
|
|
|
|
|
|
|
|
$ |
275.8 |
|
|
$ |
175.8 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
13
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net Sales |
|
Operating Profit |
|
|
Six Months Ended |
|
Six Months Ended |
|
|
June 30, |
|
June 30, |
|
|
2005 |
|
2004 |
|
2005 |
|
2004 |
Americas |
|
$ |
975.1 |
|
|
$ |
854.9 |
|
|
$ |
509.0 |
|
|
$ |
441.1 |
|
Europe |
|
|
462.7 |
|
|
|
412.8 |
|
|
|
165.0 |
|
|
|
144.4 |
|
Asia Pacific |
|
|
237.5 |
|
|
|
211.9 |
|
|
|
106.7 |
|
|
|
89.4 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total |
|
$ |
1,675.3 |
|
|
$ |
1,479.6 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Inventory step-up |
|
|
|
|
|
|
|
|
|
|
(4.1 |
) |
|
|
(49.6 |
) |
Acquisition and integration |
|
|
|
|
|
|
|
|
|
|
(27.0 |
) |
|
|
(55.5 |
) |
Global operations and corporate functions |
|
|
|
|
|
|
|
|
|
|
(216.2 |
) |
|
|
(240.2 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Operating profit |
|
|
|
|
|
|
|
|
|
$ |
533.4 |
|
|
$ |
329.6 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Product category net sales are as follows (in millions):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net Sales |
|
Net Sales |
|
|
Three Months Ended |
|
Six Months Ended |
|
|
June 30, |
|
June 30, |
|
|
2005 |
|
2004 |
|
2005 |
|
2004 |
Reconstructive implants |
|
$ |
704.9 |
|
|
$ |
607.8 |
|
|
$ |
1,394.3 |
|
|
$ |
1,219.1 |
|
Trauma |
|
|
44.4 |
|
|
|
43.4 |
|
|
|
89.8 |
|
|
|
88.4 |
|
Spine |
|
|
41.1 |
|
|
|
33.8 |
|
|
|
79.4 |
|
|
|
67.3 |
|
Orthopaedic surgical products |
|
|
56.4 |
|
|
|
52.4 |
|
|
|
111.8 |
|
|
|
104.8 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total |
|
$ |
846.8 |
|
|
$ |
737.4 |
|
|
$ |
1,675.3 |
|
|
$ |
1,479.6 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
12. Commitments and Contingencies
As a result of the Centerpulse transaction, the Company acquired the entity involved in
Centerpulses hip and knee implant litigation matter. The litigation was a result of a voluntary
recall of certain hip and knee implants manufactured and sold by Centerpulse. On March 13, 2002, a
U.S. Class Action Settlement Agreement (Settlement Agreement) was entered into by Centerpulse
that resolved U.S. claims related to the affected products and a settlement trust (Settlement
Trust) was established and funded for the most part by Centerpulse. The court approved the
settlement arrangement on May 8, 2002. Under the terms of the Settlement Agreement, the Company
will reimburse the Settlement Trust a specified amount for each revision surgery over 4,000 and
revisions on reprocessed shells over 64. As of June 28, 2005, the claims administrator has
received 4,137 likely valid claims for hips (cut-off date June 5, 2003) and knees (cut-off date
November 17, 2003) and 201 claims for reprocessed shells (cut-off
date September 8, 2004). The Company believes the litigation liability recorded as of June 30,
2005 is adequate to provide for any future claims regarding the hip and knee implant litigation.
14
On February 6, 2004, BTG International Limited (BTG) filed an action against the Company and
two unrelated parties in the United States District Court for the District of Delaware alleging
infringement by the defendants of U.S. Patent No. 6,352,559 (the 559 Patent). The Companys
Trilogy® Acetabular System was specifically accused of infringement, as well as Centerpulses
Converge® and Allofit Acetabular Systems. BTGs complaint sought unspecified
damages and injunctive relief. On March 4, 2004, the Company filed an answer to the complaint
denying infringement, and asserting a counterclaim alleging that the 559 Patent is invalid.
During May of 2005, the Company and BTG reached a final settlement with respect to all active
litigation. The settlement fully resolved the patent infringement actions in the United States and
Germany relating to the 559 Patent and the other two-part hip cup patents, as well as cases filed
by the Company against BTG in Germany and in the State of Indiana. The Companys reserves recorded
for this matter were adequate to provide for the terms of the settlement of this lawsuit. The
difference between the reserves and the settlement resulted in a decrease to costs of products
sold.
On February 15, 2005, Howmedica Osteonics Corp. (Howmedica) filed an action against the
Company and an unrelated party in the United States District Court for the District of New Jersey
alleging infringement by the defendants of U.S. Patent Nos. 6,174,934; 6,372,814; 6,664,308; and
6,818,020. Howmedicas complaint seeks unspecified damages and injunctive relief. On April 14,
2005, the Company filed its answer to the complaint denying Howmedicas allegations. The Company
believes that its defenses are valid and meritorious and the Company intends to defend the
Howmedica lawsuit vigorously.
The Company is also subject to product liability and other claims and lawsuits arising in the
ordinary course of business, for which the Company maintains insurance, subject to self-insured
retention limits. The Company establishes accruals for product liability and other claims in
conjunction with outside counsel based on current information and historical settlement information
for open claims, related fees and for claims incurred but not reported. While it is not possible
to predict with certainty the outcome of these cases, it is the opinion of management that, upon
ultimate resolution, these cases will not have a material adverse effect on the consolidated
financial position, results of operations or cash flows of the Company.
On July 25, 2003, the Staff of the Securities and Exchange Commission informed Centerpulse
that it was conducting an informal investigation of Centerpulse relating to certain accounting
issues. The Company is continuing to fully cooperate with the Securities and Exchange Commission
in this matter.
On March 31, 2005, the Company received a subpoena from the United States Department of
Justice through the United States Attorneys Office in Newark, New Jersey, requesting that the
Company produce documents for the period beginning January 2002 through March 2005 pertaining to
consulting contracts, professional service agreements and other agreements by which the Company may
provide remuneration to orthopaedic surgeons. The Company has produced documents in response to
the subpoena. The Company is cooperating fully with federal authorities with regard to this
matter. The Company understands that similar inquiries were directed to at least four other
companies in the orthopaedics industry.
15
Item 2. Managements Discussion and Analysis of Financial Condition and Results of Operations
Overview
Zimmer Holdings, Inc. is a global leader in the design, development, manufacture and marketing
of reconstructive orthopaedic implants, including joint and dental, spinal implants, and trauma
products and related orthopaedic surgical products (sometimes referred to herein as OSP).
Reconstructive orthopaedic implants restore joint function lost due to disease or trauma in joints
such as knees, hips, shoulders and elbows. Dental reconstructive implants restore function and
aesthetics in patients that have lost teeth due to trauma or disease. Spinal implants are utilized
by orthopaedic surgeons and neurosurgeons in the treatment of degenerative diseases, deformities
and trauma in all regions of the spine. Trauma products are devices used primarily to reattach or
stabilize damaged bone and tissue to support the bodys natural healing process. OSP include
supplies and instruments designed to aid in orthopaedic surgical procedures. With operations in
more than 24 countries and products marketed in more than 100 countries, operations are managed
through three reportable geographic segments the Americas, Europe and Asia Pacific. As used in
this discussion, the Company means Zimmer Holdings, Inc. and its subsidiaries.
The Company believes that the following developments or trends are important to understanding
the Companys financial condition, results of operations and cash flows for the three and six month
periods ended June 30, 2005.
Acquisition of Centerpulse
The Company continues to make progress on the integration of Centerpulse. As of June 30,
2005, the Company has completed over 73 percent of the 3,522 scheduled milestones required to
execute the entire integration plan. Remaining integration milestones relate primarily to the
completion of the manufacturing integration plan, including the shut-down of manufacturing
operations in Austin, Texas. In addition to the remaining manufacturing integration milestones,
other integration activities still to be completed include the establishment of common information
technology systems and certain warehouse consolidations, which the Company expects to complete by
the end of 2006.
Net synergies associated with the acquisition and integration of Centerpulse are currently
expected to approximate $66 million in 2005, compared to an original estimate of $56 million. The
Company defines net synergies as expense synergies less operating profit reductions resulting from
integration related sales losses and increases in operating expenses directly resulting from the
acquisition. As anticipated, only modest expense synergies have been recognized in cost of
products sold during the first and second quarters of 2005. More significant cost of products sold
synergies are expected to be recognized late in 2005 and 2006 upon completion of the transfer of
production from Centerpulses U.S. manufacturing facility in Austin, Texas, to other Company
manufacturing facilities in Warsaw, Indiana, Winterthur, Switzerland and Ponce, Puerto Rico.
Operating expense synergies, principally in selling, general and administrative expenses, have
exceeded the Companys original expectations, reflecting more rapid than expected execution and
achievement of operational efficiencies. However, these expense synergies were partially offset by
integration related sales losses, also anticipated. Net
16
synergies for 2006 are currently expected to be in excess of $100 million compared to the
Companys original estimate of $70 to $90 million.
The Company incurred $10.1 million and $27.0 million of Centerpulse acquisition and
integration expenses during the three and six month periods ended June 30, 2005, respectively, and
expects to incur an additional $18.8 million of Centerpulse acquisition and integration expenses
during the remainder of 2005.
Acquisition of Implex
The Company completed the acquisition of Implex Corp. on April 23, 2004. The acquisition was
a culmination of a distribution and strategic alliance agreement relating to the development and
distribution of reconstructive implant and trauma products incorporating Trabecular Metal
Technology. Pursuant to the former distribution and strategic alliance agreement, the
Company sold products incorporating Trabecular Metal Technology, which represented over 90 percent
of Implex sales.
Gross profit margins on sales of Company products incorporating Trabecular Metal Technology
are expected to improve throughout the balance of 2005 as the Company begins to sell a greater mix
of products manufactured post acquisition. Sales of products manufactured post acquisition include
a manufacturing and distribution profit margin, compared to only a distribution margin on sales of
products purchased from Implex pursuant to the former distribution and strategic alliance
agreement. In addition, due to increased demand for products incorporating Trabecular Metal
Technology, the Company has tripled its Trabecular Metal Technology manufacturing capacity.
Demand (Volume and Mix) Trends
Volume and mix improvements contributed 12 and 10 percentage points of sales growth during the
three and six month periods ended June 30, 2005, respectively, compared to 9 percentage points of
growth in the same 2004 periods. Orthopaedic procedure volume on a global basis continues to rise
at mid to high single digit rates driven by an aging global population, proven clinical benefits,
new material technologies, advances in surgical techniques (such as the Companys Minimally
Invasive Solutions (MIS) Procedures and Technologies) and more active
lifestyles, among other factors. In addition, the continued shift in demand to premium products,
such as Longevity® and Durasul® Highly Crosslinked Polyethylene Liners, Trabecular Metal
Technology products, high flex knees, knee revision products and porous hip stems, continue to
positively affect sales growth. For the three month period ended June 30, 2005, primary porous hip
stems accounted for 60 percent of all primary hip stem units sold, compared to 58 percent of total
primary hip stem units sold for the year ended December 31, 2004.
The Company believes innovative surgical approaches will continue to significantly impact the
orthopaedics industry. The Company has made significant progress in the development and
introduction of MIS Procedures and Technologies. During the six month period ended June 30, 2005,
The Zimmer Institute and its satellite locations trained approximately 1,150 surgeons on advanced
techniques, including over 1,000 surgeons on MIS Techniques, approximately double the number of
surgeons trained in the same period last year. In addition, during the first quarter
17
of 2005, the Company launched a new procedure for minimally invasive joint replacement, the
Zimmer® MIS Anterolateral Hip Replacement Procedure, and began training surgeons on this procedure at The
Zimmer Institute and its satellite locations. Also, in June 2005 the Company fully released the
first modular stemmed tibial prosthesis that can be assembled within the patient, making it more
conducive to minimally invasive procedures. The NexGen® MIS Tibial Component was cleared for use
in the United States and achieved $1.2 million of sales for the quarter. During the three month
period ended June 30, 2005, the Company estimates that 50 percent of all Zimmer U.S. hip and 43
percent of all Zimmer U.S. knee procedures performed with a legacy Zimmer implant utilized an MIS
Procedure and/or Technology.
Pricing Trends
Price increases contributed 1 percentage point of sales growth during both the three and six
month periods ended June 30, 2005, compared to 2 percentage points in the same 2004 periods. The
reduced benefit from average selling price increases is primarily attributed to the Americas
operating segment. The Americas experienced a 1 and 2 percent increase in average selling price
during the three and six month periods ended June 30, 2005, respectively, compared to a 4 percent
increase in the same 2004 periods. The Company believes the slower growth in average selling
prices was primarily due to hospital cost containment efforts. In Europe, average selling prices
for the three and six month periods ended June 30, 2005 were consistent with the same 2004 periods.
Within Europe, Germany has experienced a 6 percent decrease in average selling prices for both the
three and six month periods ended June 30, 2005, as a result of reductions in government implant
reimbursement rates. The decline in Germany was offset by increased average selling prices in
other European markets. Asia Pacific average selling prices were flat during the three month
period ended June 30, 2005, compared to a 3 percent decline in the same 2004 period. Effective
April 1, 2004, the Japanese government reduced reimbursement rates. Therefore, this decrease has
been fully anniversaried and in Japan average selling prices increased by 1 percentage point in the
second quarter of 2005 compared to a decrease of 5 percentage points in the same 2004 period. For
the six month period ended June 30, 2005, Japan average selling prices have decreased 2 percentage
points as the first quarter of 2005 would have been impacted by the April 1, 2004 reduction. The
next Japanese reimbursement change is not expected until April 1, 2006, and therefore Japanese
average selling prices are not expected to decline through the first quarter of 2006 compared to
the same periods in the prior year. Pressure from governmental healthcare cost containment
efforts, group purchasing organizations and potential gain sharing arrangements between surgeons
and hospitals may negatively affect the Companys ability to realize global price increases.
Foreign Currency Exchange Rates
A weakened U.S. dollar versus most currencies during the three and six month periods ended
June 30, 2005, compared to the same 2004 period, contributed 2 percentage points of sales growth.
The Company addresses currency risk management through regular operating and financing activities,
and under appropriate circumstances and subject to proper authorization, through the use of simple
forward contracts solely for managing foreign currency volatility and risk. Therefore, while
changes to foreign currency exchange rates may affect sales growth, the impact on net earnings in
the near term is usually minimal.
18
New Product Sales
New products, which management defines as products introduced within the prior 36-month
period, accounted for 20 percent, or $171 million, of the Companys sales during the three month
period ended June 30, 2005. Adoption rates for new technologies are a key indicator of industry
performance. Company sales have grown with the introduction of new products, such as Trabecular
Metal Modular Acetabular Cups. Introduced to the U.S. market in the second half of 2003,
Trabecular Metal Modular Acetabular Cups represented approximately 40 percent of all U.S.
acetabular cup sales for the three month period ended June 30, 2005. Adoption rates for the
Companys new products should continue to favorably affect the Companys operating performance.
Second Quarter Results of Operations
Three Month Results of Operations
Net Sales by Operating Segment
The following table presents net sales by operating segment and the components of the
percentage changes (dollars in millions):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended June 30, |
|
|
|
|
|
Volume/ |
|
|
|
|
|
Foreign |
|
|
2005 |
|
2004 |
|
% Inc |
|
Mix |
|
Price |
|
Exchange |
Americas |
|
$ |
494.7 |
|
|
$ |
432.2 |
|
|
|
15 |
% |
|
|
13 |
% |
|
|
1 |
% |
|
|
1 |
% |
Europe |
|
|
228.1 |
|
|
|
197.7 |
|
|
|
15 |
|
|
|
11 |
|
|
|
|
|
|
|
4 |
|
Asia Pacific |
|
|
124.0 |
|
|
|
107.5 |
|
|
|
15 |
|
|
|
11 |
|
|
|
|
|
|
|
4 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ |
846.8 |
|
|
$ |
737.4 |
|
|
|
15 |
|
|
|
12 |
|
|
|
1 |
|
|
|
2 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Foreign Exchange as used in the tables herein represents the effect of changes in foreign
exchange rates on sales growth.
19
Net Sales by Product Category
The following table presents net sales by product category and the components of the
percentage changes (dollars in millions):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended June 30, |
|
|
|
|
|
Volume/ |
|
|
|
|
|
Foreign |
|
|
2005 |
|
2004 |
|
% Inc |
|
Mix |
|
Price |
|
Exchange |
Reconstructive |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Knees |
|
$ |
353.4 |
|
|
$ |
294.2 |
|
|
|
20 |
% |
|
|
17 |
% |
|
|
1 |
% |
|
|
2 |
% |
Hips |
|
|
294.3 |
|
|
|
267.7 |
|
|
|
10 |
|
|
|
7 |
|
|
|
|
|
|
|
3 |
|
Dental |
|
|
40.2 |
|
|
|
31.4 |
|
|
|
28 |
|
|
|
26 |
|
|
|
|
|
|
|
2 |
|
Extremities |
|
|
17.0 |
|
|
|
14.5 |
|
|
|
17 |
|
|
|
12 |
|
|
|
3 |
|
|
|
2 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total |
|
|
704.9 |
|
|
|
607.8 |
|
|
|
16 |
|
|
|
13 |
|
|
|
1 |
|
|
|
2 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Trauma |
|
|
44.4 |
|
|
|
43.4 |
|
|
|
2 |
|
|
|
(3 |
) |
|
|
3 |
|
|
|
2 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Spine |
|
|
41.1 |
|
|
|
33.8 |
|
|
|
22 |
|
|
|
20 |
|
|
|
1 |
|
|
|
1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
OSP |
|
|
56.4 |
|
|
|
52.4 |
|
|
|
8 |
|
|
|
5 |
|
|
|
1 |
|
|
|
2 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total |
|
$ |
846.8 |
|
|
$ |
737.4 |
|
|
|
15 |
|
|
|
12 |
|
|
|
1 |
|
|
|
2 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Knee sales were led by the NexGen Complete Knee Solution product line including the NexGen
LPS-Flex Knee, NexGen Trabecular Metal Tibial Components, the NexGen CR-Flex Knee, the NexGen
Rotating Hinge Knee and the NexGen LCCK Revision Knee. In addition, the Innex Total
Knee System and the Zimmer Unicompartmental High Flex Knee exhibited strong growth.
Hip sales were led by growth in porous stems, including significant combined growth of the
VerSys® Fiber Metal and Zimmer M/L Taper Stems, Trabecular Metal Acetabular Cups,
Durom® Hip Resurfacing Products internationally, and Longevity and
Durasul Highly Crosslinked Polyethylene Liners. The CLS® Spotorno® Taper Stem also had strong
growth.
Dental sales were led by biologicals and prosthetic implants, including strong growth of the
Tapered Screw-Vent® Implant System. Extremities sales were led by the Bigliani/Flatow®
Complete Shoulder Solution and the Anatomical Shoulder System. Trauma sales were
led by sales of Zimmer Periarticular Plates and
ITST
Intertrochanteric/Subtrochanteric Fixation. Spine
sales were led by the Dynesys®1 Dynamic Stabilization System and Spinal Trabecular
Metal Spacers. OSP sales were primarily driven by the continued growth of the
OrthoPAT®2 Autotransfusion System and wound management and drainage products.
|
|
|
1 |
|
The Dynesys Dynamic Stabilization Spinal
System is cleared in the United States for use as an adjunct to fusion. The
Dynesys Dynamic Stabilization Spinal System is also currently in an
investigational device study for a non-fusion application and is limited by
U.S. federal law to investigational use only.
2 Trademark of Haemonetics Corporation |
20
Americas Net Sales
The following table presents Americas net sales (dollars in millions):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended June 30, |
|
|
|
|
2005 |
|
2004 |
|
% Inc (Dec) |
Reconstructive |
|
|
|
|
|
|
|
|
|
|
|
|
Knees |
|
$ |
225.6 |
|
|
$ |
186.4 |
|
|
|
21 |
% |
Hips |
|
|
137.6 |
|
|
|
126.7 |
|
|
|
9 |
|
Dental |
|
|
23.2 |
|
|
|
18.6 |
|
|
|
24 |
|
Extremities |
|
|
11.7 |
|
|
|
10.0 |
|
|
|
17 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total |
|
|
398.1 |
|
|
|
341.7 |
|
|
|
17 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Trauma |
|
|
26.2 |
|
|
|
26.9 |
|
|
|
(2 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
Spine |
|
|
32.8 |
|
|
|
27.3 |
|
|
|
20 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
OSP |
|
|
37.6 |
|
|
|
36.3 |
|
|
|
4 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total |
|
$ |
494.7 |
|
|
$ |
432.2 |
|
|
|
15 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Growth in the Americas was led by strong knee and hip sales. Knee sales were led by the
NexGen Complete Knee Solution product line, including the NexGen LPS-Flex Knee, NexGen Trabecular
Metal Tibial Components, the NexGen LCCK Revision Knee and the NexGen CR-Flex Knee.
Prolong Highly Crosslinked Polyethylene and the Zimmer Unicompartmental High Flex
Knee also made strong contributions.
Hip sales were led by growth in porous stems, including significant combined growth of the
VerSys Fiber Metal and Zimmer M/L Taper Stems, Trabecular Metal Acetabular Cups and Longevity and
Durasul Highly Crosslinked Polyethylene Liners.
Dental, Extremities and Spine also experienced double digit percentage growth compared to the
prior year quarter. Dental sales were led by the Tapered Screw-Vent Implant System. Extremities
sales were led by the Bigliani/Flatow Complete Shoulder Solution. Spine sales were led by the
Dynesys Dynamic Stabilization System.
21
Europe Net Sales
The following table presents Europe net sales (dollars in millions):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended June 30, |
|
|
|
|
2005 |
|
2004 |
|
% Inc (Dec) |
Reconstructive |
|
|
|
|
|
|
|
|
|
|
|
|
Knees |
|
$ |
84.6 |
|
|
$ |
71.9 |
|
|
|
18 |
% |
Hips |
|
|
106.4 |
|
|
|
95.9 |
|
|
|
11 |
|
Dental |
|
|
11.6 |
|
|
|
9.2 |
|
|
|
27 |
|
Extremities |
|
|
3.7 |
|
|
|
3.0 |
|
|
|
24 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total |
|
|
206.3 |
|
|
|
180.0 |
|
|
|
15 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Trauma |
|
|
8.5 |
|
|
|
7.5 |
|
|
|
13 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Spine |
|
|
6.7 |
|
|
|
5.7 |
|
|
|
18 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
OSP |
|
|
6.6 |
|
|
|
4.5 |
|
|
|
47 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total |
|
$ |
228.1 |
|
|
$ |
197.7 |
|
|
|
15 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Growth in Europe was led by strong knee and hip sales, primarily the NexGen Complete Knee
Solution product line and the Innex Total Knee System. Hip sales growth was negatively impacted by
reduced average selling prices in Germany and contemplated sales losses related to the Centerpulse
integration. Hip sales were driven by Longevity and Durasul Highly Crosslinked Polyethylene
Liners, Durom Hip Resurfacing, Trabecular Metal Acetabular Cups and the CLS Spotorno Taper Stem.
Dental, Extremities, Trauma, Spine and OSP also experienced double digit percentage growth
compared to the prior year quarter. Dental sales were led by the Tapered Screw-Vent Implant
System. Extremities sales were led by the Bigliani/Flatow Complete Shoulder Solution and the
Anatomical Shoulder System. Trauma sales were led by cable products. Spine sales were led by the
Dynesys Dynamic Stabilization System. OSP sales were led by wound management products.
22
Asia Pacific Net Sales
The following table presents Asia Pacific net sales (dollars in millions):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended June 30, |
|
|
|
|
2005 |
|
2004 |
|
% Inc |
Reconstructive |
|
|
|
|
|
|
|
|
|
|
|
|
Knees |
|
$ |
43.2 |
|
|
$ |
35.9 |
|
|
|
20 |
% |
Hips |
|
|
50.3 |
|
|
|
45.1 |
|
|
|
12 |
|
Dental |
|
|
5.4 |
|
|
|
3.6 |
|
|
|
53 |
|
Extremities |
|
|
1.6 |
|
|
|
1.5 |
|
|
|
7 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total |
|
|
100.5 |
|
|
|
86.1 |
|
|
|
17 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Trauma |
|
|
9.7 |
|
|
|
9.0 |
|
|
|
7 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Spine |
|
|
1.6 |
|
|
|
0.8 |
|
|
|
106 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
OSP |
|
|
12.2 |
|
|
|
11.6 |
|
|
|
6 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total |
|
$ |
124.0 |
|
|
$ |
107.5 |
|
|
|
15 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Growth in Asia Pacific was led by strong knee and hip sales. Knee sales were driven by NexGen
Trabecular Metal Tibial Components, the NexGen CR Knee and the NexGen LPS-Flex Knee. Hip sales
were driven primarily by the continued conversion to porous stems, including the VerSys Hip System,
the Alloclassic® (Zweymueller®) Hip System and the CLS Spotorno Stem and sales of Longevity Highly
Crosslinked Polyethylene Liners.
Dental and Spine also experienced double digit percentage growth compared to the prior year
quarter. Dental sales were led by the Tapered Screw-Vent Implant System and the Tapered SwissPlus®
Implant System. Spine sales were led by the ST360°TM Spinal Fixation System.
Gross Profit
Gross profit as a percentage of net sales was 77.7 percent in the three month period ended
June 30, 2005, compared to 77.0 for the three month period ended March 31, 2005. The primary
difference between the first and second quarters of 2005 is attributed to approximately $6.5
million of pre-tax income reflected in costs of products sold related to the favorable resolution
of certain legal and other matters, including the BTG settlement described in Note 12 to the
interim consolidated financial statements. These items contributed 0.8 percent to gross profit
margin and approximately $0.02 to diluted earnings per share.
Gross profit as a percentage of net sales was 72.6 percent in the three month period ended
June 30, 2004. Inventory step-up costs in the three month period ended June 30, 2005 decreased to
$2.1 million, or 0.3 percent of sales, compared to $18.6 million, or 2.5 percent of sales, in the
same 2004 period. Other primary contributors to the improvement in gross profit margin were
reduced excess and obsolete inventory expense due to improved inventory management, favorable
resolution of certain legal and other matters, including the BTG settlement described in Note 12 to
the interim consolidated financial statements, favorable product category mix,
23
reduced royalties
and integration related synergies. Product category mix had a positive effect on gross margins due
to higher sales growth of more profitable reconstructive implants and spinal products compared to
trauma and OSP products, and the continued shift to premium products. Royalty expenses as a
percentage of sales declined due to the expiration of certain royalty contracts and reductions in
certain contractual royalty rates.
Operating Expenses
R&D as a percentage of net sales was 5.1 percent for the three month period ended June 30,
2005, compared to 5.2 percent in the same 2004 period. R&D increased to $43.6 million for the
three month period ended June 30, 2005 from $38.2 million in the same 2004 period, reflecting
increased spending on active projects focused on areas of strategic significance, including, but
not limited to biologics. The Company targets R&D spending to the high end of what management
believes to be an average of 4-6 percent for the industry. The Company expects to increase the
total number of development projects to more than 170 and expand the number of external technology
relationships, which may increase R&D spending to approximately 5.5 percent to 6 percent of sales.
SG&A as a percentage of net sales was 38.8 percent for the three month period ended June 30,
2005, compared to 40.3 percent for the same 2004 period. The decrease was primarily due to sales
growth and realized expense synergies. The Company expects to pursue additional synergy
opportunities. In addition, low cost increases in internal and external general and administrative
expenditures and controlled general and administrative spending reduced SG&A as a percentage of
sales.
Acquisition and integration expenses for the three month period ended June 30, 2005, were
$10.1 million compared to $24.2 million for the same 2004 period, and included $2.6 million of
employee severance and retention expenses, $2.0 million of sales agent contract termination
expenses, $1.8 million of costs related to integrating the Companys information technology
systems, $1.1 million of integration consulting expenses, $0.8 million of personnel expenses and
travel for full-time integration team members, $0.7 million of facility and employee relocation
expenses and $1.1 million of other miscellaneous acquisition and integration expenses.
Operating Profit, Income Taxes and Net Earnings
Operating profit for the three month period ended June 30, 2005, increased 57 percent to
$275.8 million from $175.8 million in the same 2004 period. Operating profit growth was driven by
increased sales, improved gross profit margins, realized operating expense synergies, controlled
operating expenses and decreased acquisition and integration expenses.
The effective tax rate on earnings before income taxes and minority interest decreased to 29.7
percent for the three month period ended June 30, 2005, from 30.7 percent for the same period in
2004. The reasons for the decrease in the effective tax rate were the implementation of several
European restructuring initiatives, the successful negotiation of a lower ongoing Swiss tax rate
(from approximately 24 percent to 12.5 percent) and the continued expansion of operations in lower
tax jurisdictions.
Net earnings increased 64 percent to $190.7 million for the three month period ended June 30,
2005, compared to $116.3 million in the same 2004 period. The increase was primarily due
24
to higher
operating profit, decreased interest expense due to a lower average outstanding debt balance and a
lower effective tax rate. Basic and diluted earnings per share increased 60 percent and 62 percent
to $0.77 and $0.76, respectively, from $0.48 and $0.47 in the same 2004 period.
Operating Profit by Segment
Company management evaluates operating segment performance based upon segment operating profit
exclusive of operating expenses pertaining to global operations and corporate expenses, acquisition
and integration expenses, inventory step-up, in-process research and development write-offs and
intangible asset amortization expense. Global operations include research, development,
engineering, medical education, brand management, corporate legal, finance, human resource
functions, and U.S. and Puerto Rico based operations and logistics. Intercompany transactions have
been eliminated from segment operating profit. For more information regarding the Companys
segments, see Note 11 to the consolidated financial statements included elsewhere in this Form
10-Q.
The following table sets forth operating profit as a percentage of sales by segment for the
three month periods ended June 30, 2005 and 2004:
Percent of net sales
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended June 30, |
|
|
2005 |
|
2004 |
Americas |
|
|
52.3 |
% |
|
|
52.3 |
% |
Europe |
|
|
33.2 |
|
|
|
33.8 |
|
Asia Pacific |
|
|
44.3 |
|
|
|
41.7 |
|
In the Americas, operating profit as a percentage of sales remained consistent.
European operating profit as a percentage of net sales declined. Operating margins decreased
due to a slight decline in average selling prices and increased inventory obsolescence charges as a
percentage of sales. This decline was partially offset by the realization of expense synergies
related to the elimination of redundant functions and controlled selling, general and
administrative spending.
Asia Pacific operating profit as a percentage of net sales increased primarily due to a slight
increase in average selling prices, favorable geographic sales mix as a result of strong growth in
the Japan and Australia markets and lower royalty expenses as a percentage of sales.
25
Six Month Results of Operations
Net Sales by Operating Segment
The following table presents net sales by operating segment and the components of the
percentage changes (dollars in millions):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Six Months Ended June 30, |
|
|
|
|
|
Volume/ |
|
|
|
|
|
Foreign |
|
|
2005 |
|
2004 |
|
% Inc |
|
Mix |
|
Price |
|
Exchange |
Americas |
|
$ |
975.1 |
|
|
$ |
854.9 |
|
|
|
14 |
% |
|
|
12 |
% |
|
|
2 |
% |
|
|
|
% |
Europe |
|
|
462.7 |
|
|
|
412.8 |
|
|
|
12 |
|
|
|
7 |
|
|
|
|
|
|
|
5 |
|
Asia Pacific |
|
|
237.5 |
|
|
|
211.9 |
|
|
|
12 |
|
|
|
9 |
|
|
|
(1 |
) |
|
|
4 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ |
1,675.3 |
|
|
$ |
1,479.6 |
|
|
|
13 |
|
|
|
10 |
|
|
|
1 |
|
|
|
2 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net Sales by Product Category
The following table presents net sales by product category and the components of the
percentage changes (dollars in millions):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Six Months Ended June 30, |
|
|
|
|
|
Volume/ |
|
|
|
|
|
Foreign |
|
|
2005 |
|
2004 |
|
% Inc |
|
Mix |
|
Price |
|
Exchange |
Reconstructive |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Knees |
|
$ |
701.1 |
|
|
$ |
587.0 |
|
|
|
19 |
% |
|
|
16 |
% |
|
|
1 |
% |
|
|
2 |
% |
Hips |
|
|
586.5 |
|
|
|
543.3 |
|
|
|
8 |
|
|
|
5 |
|
|
|
|
|
|
|
3 |
|
Dental |
|
|
73.1 |
|
|
|
59.2 |
|
|
|
24 |
|
|
|
20 |
|
|
|
2 |
|
|
|
2 |
|
Extremities |
|
|
33.6 |
|
|
|
29.6 |
|
|
|
14 |
|
|
|
8 |
|
|
|
4 |
|
|
|
2 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total |
|
|
1,394.3 |
|
|
|
1,219.1 |
|
|
|
14 |
|
|
|
11 |
|
|
|
1 |
|
|
|
2 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Trauma |
|
|
89.8 |
|
|
|
88.4 |
|
|
|
1 |
|
|
|
(2 |
) |
|
|
2 |
|
|
|
1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Spine |
|
|
79.4 |
|
|
|
67.3 |
|
|
|
18 |
|
|
|
16 |
|
|
|
1 |
|
|
|
1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
OSP |
|
|
111.8 |
|
|
|
104.8 |
|
|
|
7 |
|
|
|
4 |
|
|
|
1 |
|
|
|
2 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total |
|
$ |
1,675.3 |
|
|
$ |
1,479.6 |
|
|
|
13 |
|
|
|
10 |
|
|
|
1 |
|
|
|
2 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Knee sales were led by the NexGen Complete Knee Solution product line including the NexGen
LPS-Flex Knee, NexGen Trabecular Metal Tibial Components, the NexGen CR-Flex Knee, the NexGen
Rotating Hinge Knee and the NexGen LCCK Revision Knee. In addition, the Innex Total Knee System
and the Zimmer Unicompartmental High Flex Knee exhibited strong growth.
26
Hip sales were led by growth in porous stems, including significant combined growth of the
VerSys Fiber Metal and Zimmer M/L Taper Stems, Trabecular Metal Acetabular Cups, Durom Hip Resurfacing Products internationally, and Longevity and Durasul Highly
Crosslinked Polyethylene Liners. The CLS Spotorno Taper Stem also had strong growth.
Dental sales were led by biologicals and prosthetic implants, including strong growth of the
Tapered Screw-Vent Implant System. Extremities sales were led by the Bigliani/Flatow Complete
Shoulder Solution and the Anatomical Shoulder System. Trauma sales were led by sales of Zimmer
Periarticular Plates and ITST
Intertrochanteric/Subtrochanteric Fixation. Spine sales were led by the Dynesys Dynamic
Stabilization System and Spinal Trabecular Metal Spacers. OSP sales were primarily driven by the
continued growth of the OrthoPAT Autotransfusion System and wound management and drainage products.
Americas Net Sales
The following table presents Americas net sales (dollars in millions):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Six Months Ended June 30, |
|
|
|
|
2005 |
|
2004 |
|
% Inc (Dec) |
Reconstructive |
|
|
|
|
|
|
|
|
|
|
|
|
Knees |
|
$ |
447.9 |
|
|
$ |
368.9 |
|
|
|
21 |
% |
Hips |
|
|
269.9 |
|
|
|
248.0 |
|
|
|
9 |
|
Dental |
|
|
42.1 |
|
|
|
35.0 |
|
|
|
21 |
|
Extremities |
|
|
23.3 |
|
|
|
20.6 |
|
|
|
14 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total |
|
|
783.2 |
|
|
|
672.5 |
|
|
|
17 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Trauma |
|
|
52.4 |
|
|
|
54.6 |
|
|
|
(4 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
Spine |
|
|
64.5 |
|
|
|
56.0 |
|
|
|
15 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
OSP |
|
|
75.0 |
|
|
|
71.8 |
|
|
|
5 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total |
|
$ |
975.1 |
|
|
$ |
854.9 |
|
|
|
14 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Growth in the Americas was led by strong knee and hip sales. Knee sales were led by the
NexGen Complete Knee Solution product line, including the NexGen LPS-Flex Knee, NexGen Trabecular
Metal Tibial Components, the NexGen LCCK Revision Knee and the NexGen CR-Flex Knee. Prolong Highly
Crosslinked Polyethylene and the Zimmer Unicompartmental High Flex Knee also made strong
contributions.
Hip sales were led by growth in porous stems, including significant combined growth of the
VerSys Fiber Metal and Zimmer M/L Taper Stems, Trabecular Metal Acetabular Cups and Longevity and
Durasul Highly Crosslinked Polyethylene Liners.
Dental, Extremities and Spine also experienced double digit percentage growth compared to the
prior year six month period. Dental sales were led by the Tapered Screw-Vent Implant System.
Extremities sales were led by the Bigliani/Flatow Complete Shoulder Solution. Spine sales were led
by the Dynesys Dynamic Stabilization System.
27
Europe Net Sales
The following table presents Europe net sales (dollars in millions):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Six Months Ended June 30, |
|
|
|
|
2005 |
|
2004 |
|
% Inc |
Reconstructive |
|
|
|
|
|
|
|
|
|
|
|
|
Knees |
|
$ |
173.1 |
|
|
$ |
148.6 |
|
|
|
17 |
% |
Hips |
|
|
218.2 |
|
|
|
205.0 |
|
|
|
6 |
|
Dental |
|
|
22.0 |
|
|
|
17.8 |
|
|
|
23 |
|
Extremities |
|
|
7.1 |
|
|
|
6.1 |
|
|
|
17 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total |
|
|
420.4 |
|
|
|
377.5 |
|
|
|
11 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Trauma |
|
|
17.0 |
|
|
|
14.8 |
|
|
|
15 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Spine |
|
|
12.1 |
|
|
|
10.0 |
|
|
|
20 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
OSP |
|
|
13.2 |
|
|
|
10.5 |
|
|
|
26 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total |
|
$ |
462.7 |
|
|
$ |
412.8 |
|
|
|
12 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Growth in Europe was led by strong knee sales, primarily the NexGen Complete Knee Solution
product line and the Innex Total Knee System. Hip sales growth was negatively impacted by reduced
average selling prices in Germany and contemplated sales losses related to the Centerpulse
integration. Hip sales were driven by Longevity and Durasul Highly Crosslinked Polyethylene
Liners, Durom Hip Resurfacing, Trabecular Metal Acetabular Cups and the CLS Spotorno Taper Stem.
Dental, Extremities, Trauma, Spine and OSP also experienced double digit percentage growth
compared to the prior year six month period. Dental sales were led by the Tapered Screw-Vent
Implant System. Extremities sales were led by the Bigliani/Flatow Complete Shoulder Solution and
the Anatomical Shoulder System. Trauma sales were led by cable products. Spine sales were led by
the Dynesys Dynamic Stabilization System. OSP sales were led by wound management products.
28
Asia Pacific Net Sales
The following table presents Asia Pacific net sales (dollars in millions):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Six Months Ended June 30, |
|
|
|
|
2005 |
|
2004 |
|
% Inc |
Reconstructive |
|
|
|
|
|
|
|
|
|
|
|
|
Knees |
|
$ |
80.1 |
|
|
$ |
69.5 |
|
|
|
15 |
% |
Hips |
|
|
98.4 |
|
|
|
90.3 |
|
|
|
9 |
|
Dental |
|
|
9.0 |
|
|
|
6.4 |
|
|
|
40 |
|
Extremities |
|
|
3.2 |
|
|
|
2.9 |
|
|
|
9 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total |
|
|
190.7 |
|
|
|
169.1 |
|
|
|
13 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Trauma |
|
|
20.4 |
|
|
|
19.0 |
|
|
|
8 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Spine |
|
|
2.8 |
|
|
|
1.3 |
|
|
|
120 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
OSP |
|
|
23.6 |
|
|
|
22.5 |
|
|
|
5 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total |
|
$ |
237.5 |
|
|
$ |
211.9 |
|
|
|
12 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Growth in Asia Pacific was led by strong knee and hip sales. Knee sales were driven by NexGen
Trabecular Metal Tibial Components, the NexGen CR Knee and the NexGen LPS-Flex Knee. Hip sales
were driven primarily by the continued conversion to porous stems, including the VerSys Hip System,
the Alloclassic (Zweymueller) Hip System and the CLS Spotorno Stem, and sales of Longevity Highly
Crosslinked Polyethylene Liners.
Dental and Spine also experienced double digit percentage growth compared to the prior year
six month period. Dental sales were led by the Tapered Screw-Vent Implant System and the Tapered
SwissPlus Implant System. Spine sales were led by the ST360° Spinal Fixation System.
Gross Profit
Gross profit as a percentage of net sales was 77.4 percent in the six month period ended June
30, 2005, compared to 71.5 in the same 2004 period. Inventory step-up costs in the six month
period ended June 30, 2005 decreased to $4.1 million, or 0.2 percent of sales, compared to $49.6
million, or 3.4 percent of sales, in the same 2004 period. Costs of products sold was reduced by
approximately $6.5 million, or 0.4 percent of sales and approximately $0.02 diluted earnings per
share, due to the favorable resolution of certain legal and other matters, including the BTG
settlement described in Note 12 to the interim consolidated financial statements. Other primary
contributors to the improvement in gross profit margin were favorable operating segment and product
category mix, reduced royalties and integration related synergies. Operating segment mix and
product category mix both had a positive effect on gross margins due to higher sales growth in the
more profitable Americas segment compared to Europe and Asia Pacific, higher sales growth of more
profitable reconstructive implants and spinal products compared to trauma and OSP products, and the continued shift to premium products. Royalty expenses as a
29
percentage of sales declined due to the
expiration of certain royalty contracts and reductions in certain contractual royalty rates.
Operating Expenses
R&D as a percentage of net sales was 5.1 percent for the six month period ended June 30, 2005,
compared to 5.3 percent in the same 2004 period. R&D increased to $85.7 million for the six month
period ended June 30, 2005 from $78.0 million in the same 2004 period, reflecting increased
spending on active projects focused on areas of strategic significance, including, but not limited
to biologics. The Company targets R&D spending to the high end of what management believes to be
an average of 4-6 percent for the industry. The Company expects to increase the total number of
development projects to more than 170 and expand the number of external technology relationships,
which may increase R&D spending to approximately 5.5 percent to 6 percent of sales.
SG&A as a percentage of net sales was 38.8 percent for the six month period ended June 30,
2005, compared to 40.2 percent for the same 2004 period. The decrease was primarily due to sales
growth and realized expense synergies. The Company expects to pursue additional synergy
opportunities. In addition, low cost increases in internal and external general and administrative
expenditures and controlled general and administrative spending reduced SG&A as a percentage of
sales.
Acquisition and integration expenses for the six month period ended June 30, 2005, were $27.0
million compared to $55.5 million for the same 2004 period, and included $11.5 million of sales
agent contract termination expenses, $4.6 million of employee severance and retention expenses,
$4.4 million of costs related to integrating the Companys information technology systems, $2.3
million of integration consulting expenses, $1.7 million of personnel expenses and travel for
full-time integration team members, $1.3 million of facility and employee relocation expenses and
$1.2 million of other miscellaneous acquisition and integration expenses.
Operating Profit, Income Taxes and Net Earnings
Operating profit for the six month period ended June 30, 2005, increased 62 percent to $533.4
million from $329.6 million in the same 2004 period. Operating profit growth was driven by
increased sales, improved gross profit margins, realized operating expense synergies, controlled
operating expenses and decreased acquisition and integration expenses.
The effective tax rate on earnings before income taxes and minority interest decreased to 30.1
percent for the six month period ended June 30, 2005, from 31.4 percent for the same period in
2004. The reasons for the decrease in the effective tax rate were the implementation of several
European restructuring initiatives, the successful negotiation of a lower ongoing Swiss tax rate
(from approximately 24 percent to 12.5 percent) and the continued expansion of operations in lower
tax jurisdictions.
Net earnings increased 70 percent to $364.3 million for the six month period ended June 30,
2005, compared to $213.9 million in the same 2004 period. The increase was primarily due to higher
operating profit, decreased interest expense due to a lower average outstanding debt balance and a
lower effective tax rate. Basic and diluted earnings per share both increased 68 percent to $1.48
and $1.46, respectively, from $0.88 and $0.87 in the same 2004 period.
30
Operating Profit by Segment
The following table sets forth operating profit as a percentage of sales by segment for the
six month periods ended June 30, 2005 and 2004:
Percent of net sales
|
|
|
|
|
|
|
|
|
|
|
Six Months Ended June 30, |
|
|
2005 |
|
2004 |
Americas |
|
|
52.2 |
% |
|
|
51.6 |
% |
Europe |
|
|
35.7 |
|
|
|
35.0 |
|
Asia Pacific |
|
|
45.0 |
|
|
|
42.2 |
|
In the Americas, operating profit as a percentage of sales increased due to the effective
control of operating expenses, including realized expense synergies and controlled general and
administrative spending.
European operating profit as a percentage of net sales improved due to the realization of
expense synergies related to the elimination of redundant functions and controlled selling, general
and administrative spending. This increase was offset slightly due to a change in geographic mix
and a slight decrease in average selling prices.
Asia Pacific operating profit as a percentage of net sales increased primarily due to
favorable geographic sales mix as a result of strong growth in the Japan and Australia markets and
lower royalty expenses as a percentage of sales.
Liquidity and Capital Resources
Cash flows provided by operating activities were $396.1 million in the six month period ended
June 30, 2005 compared to $398.3 million in the same 2004 period. The principal source of cash for
the three month period ended June 30, 2005 was net earnings of $364.3 million. The Company
experienced $79.9 million of positive cash flow related to income taxes in the six month period
ended June 30, 2005. The Company has been able to utilize acquired Centerpulse U.S. net operating
loss carryforwards to reduce U.S. federal income tax payments. Operating cash flows from working
capital decreased compared to the same 2004 period as a result of sales growth and resolution of
certain legal matters, including the BTG settlement described in Note 12 to the interim
consolidated financial statements.
Working capital management continues to be a key focus. At June 30, 2005, the Company had 61
days of sales outstanding in accounts receivable, favorable to June 30, 2004 by 4 days and
favorable to March 31, 2005 by 1 day. The decrease in days compared to June 30, 2004 is primarily
due to improved receivable collections in Europe and Asia Pacific. At June 30, 2005, the Company
had 271 days of inventory on hand, unfavorable to June 30, 2004 by 30 days. Inventory step-up
charges and the resolution of certain legal and other matters, including the BTG settlement
described in Note 12 to the interim consolidated financial statements, has impacted the components
of this calculation by increasing net inventory levels by $6.2 million and decreasing cost of
products sold by $4.4 million ($6.5 million related to the favorable
31
resolution of certain legal
and other matters offset by $2.1 million of inventory step-up costs). The Company estimates these
charges increased days of inventory on hand by 9 days.
Cash flows used in investing activities decreased to $142.5 million in the six month period
ended June 30, 2005, compared to $203.5 million in the same 2004 period. In the six month period
ended June 30, 2004, the Company had cash outflows of $103.7 million related to the Implex
acquisition and $18.2 million related to the Centerpulse acquisition. Additions to instruments
during the six month period ended June 30, 2005 were $90.6 million compared to $74.9 million in the
same 2004 period. Increases in instrument purchases were primarily to support new product launches
and sales growth. During 2005 the Company expects purchases of instruments to approximate $145
million as the Company continues to invest in instruments to support new products, sales growth and
MIS Procedures. Additions to other property, plant and equipment during the six month period ended
June 30, 2005, were $42.2 million compared to $30.6 million in the same 2004 period. Increases
were primarily related to facility expansions in Warsaw, Indiana; Ponce, Puerto Rico; and
Parsippany, New Jersey. During 2005 the Company expects purchases of other property, plant and
equipment to approximate $125 million to $135 million, as a result of ongoing facility expansions
in Warsaw, Indiana; Ponce, Puerto Rico; Winterthur, Switzerland; and Parsippany, New Jersey.
Facility expansions are due to increased demand, the transfer of production to other Company
manufacturing sites as a result of the closure of the Austin, Texas facility and the tripling of
Trabecular Metal Technology production capacity.
Cash flows used in financing activities were $325.1 million for the six month period ended
June 30, 2005, compared to $194.7 million in the same 2004 period. The Company repaid $375.3
million of debt, net, in the six month period ended June 30, 2005, utilizing cash on hand, cash
generated from operating activities and $52.1 million in cash proceeds received from the exercise
of Company stock options.
On March 31, 2005, the Company amended and restated its revolving credit and term loan
agreement dated as of May 24, 2004 into a five year $1,350 million amended and restated credit
agreement (the Amended and Restated Facility). The Amended and Restated Facility is a revolving,
multi-currency, senior unsecured credit facility maturing March 31, 2010. Available borrowings
under the Amended and Restated Facility at June 30, 2005, were approximately $1,082 million. The
Amended and Restated Facility contains a provision whereby borrowings may be increased to $1,750
million.
The Company and certain of its wholly owned foreign and domestic subsidiaries are the
borrowers and its wholly owned domestic subsidiaries are the guarantors of the Amended and Restated
Facility. Borrowings under the Amended and Restated Facility are used for general corporate
purposes and bear interest at a LIBOR-based rate plus an applicable margin determined by reference
to the Companys senior unsecured long-term credit rating and the amounts drawn under the Amended
and Restated Facility, at an alternate base rate, or at a fixed rate determined through a
competitive bid process. The Amended and Restated Facility contains customary affirmative and
negative covenants and events of default for an unsecured financing arrangement, including, among
other things, limitations on consolidations, mergers and sales of assets. Financial covenants
include a maximum leverage ratio of 3.0 to 1.0 and a minimum interest coverage ratio of 3.5 to 1.0.
If the Company falls below an investment grade credit rating, additional restrictions would
result, including restrictions on investments and payment of dividends. The Company was in
compliance with all covenants under the Amended and
32
Restated Facility as of June 30, 2005.
Commitments under the Amended and Restated Facility are subject to certain fees, including a
facility and a utilization fee. The Amended and Restated Facility is rated BBB+ by Standard &
Poors Ratings Services and is not rated by Moodys Investors Service, Inc.
The Company also has available uncommitted credit facilities totaling $50 million.
The terms of the Implex acquisition include additional cash earn-out payments that are
contingent on the year-over-year growth of Implex product sales through 2006. The Company
estimates total earn-out payments, including $51.9 million of payments already made, to be in a
range from $120 to $160 million. The Company expects to pay future earn-out payments, if any, with
cash flows from operations and borrowings available under the Amended and Restated Facility.
The Company had $78.8 million in cash and equivalents, $16.6 million in restricted cash and
total debt of $268.1 million as of June 30, 2005. The Company expects cash on hand to be in excess
of total outstanding debt by December 31, 2005, absent any cash requirements for acquisitions.
Management believes that cash flows from operations, together with available borrowings under
the Amended and Restated Facility, will be sufficient to meet the Companys working capital,
capital expenditure and debt service needs. Should investment opportunities arise, the Company
believes that its earnings, balance sheet and cash flows will allow the Company to obtain
additional capital, if necessary.
Recent Accounting Pronouncements
In December 2004, the FASB issued SFAS No. 123(R), Share-Based Payment, which is a revision
to SFAS No. 123, Accounting for Stock Based Compensation. SFAS 123(R) requires all share-based
payments to employees, including stock options, to be expensed based on their fair values. The
Company has disclosed the effect on net earnings and earnings per share if the Company had applied
the fair value recognition provisions of SFAS 123. SFAS 123(R) contains three methodologies for
adoption: 1) adopt SFAS 123(R) on the effective date for interim periods thereafter, 2) adopt SFAS
123(R) on the effective date for interim periods thereafter and restate prior interim periods
included in the fiscal year of adoption under the provisions of SFAS 123, or 3) adopt SFAS 123(R)
on the effective date for interim periods thereafter and restate all prior interim periods under
the provisions of SFAS 123. The SEC has amended the compliance dates of SFAS 123(R) requiring
adoption in the first fiscal year beginning after June 15, 2005. The Company intends to adopt SFAS
123(R) on January 1, 2006.
In December 2004, the FASB issued FASB Staff Position (FSP) 109-2, Accounting and
Disclosure Guidance for the Foreign Earnings Repatriation Provision within the American Jobs
Creation Act of 2004 (the Act). FSP 109-2 provides accounting and disclosure guidance for
repatriation provisions included under the Act. FSP 109-2 was effective upon issuance. As a
result of the Act, the Company may repatriate earnings of foreign subsidiaries at reduced U.S. tax
rates. The Company believes the effect of such repatriation will not have a material effect on its
financial position, results of operations or cash flows and expects to complete its evaluation by
December 31, 2005.
33
In November 2004, the FASB issued SFAS No. 151, Inventory Costs to clarify the accounting
for abnormal amounts of idle facility expense. SFAS No. 151 requires that fixed overhead
production costs be applied to inventory at normal capacity and any excess fixed overhead
production costs be charged to expense in the period in which they were incurred. SFAS No. 151 is
effective for fiscal years beginning after June 15, 2005. The Company does not expect SFAS No. 151
to have a material effect on its financial position, results of operations, or cash flows.
Critical Accounting Estimates
The financial results of the Company are affected by the selection and application of
accounting policies and methods. There were no changes in the three or six month periods ended
June 30, 2005 to the application of critical accounting estimates as described in the Companys
2004 annual report on Form 10-K.
Forward Looking Statements
This quarterly report contains statements that are forward-looking statements within the
meaning of federal securities laws including statements with respect to future sales, earnings,
capital expenditures and debt repayment. When used in this report, the words may, will,
should, anticipate, estimate, expect, plan, believe, predict, potential, project,
target, forecast, intend and similar expressions are intended to identify forward-looking
statements. Forward-looking statements are subject to risks and uncertainties that could cause
actual results to differ materially from those projected. These risks and uncertainties include,
but are not limited to, price and product competition, rapid technological development, demographic
changes, dependence on new product development, the mix of our products and services, supply and
prices of raw materials and products, customer demand for our products and services, the ability to
successfully integrate acquired companies including Centerpulse AG and Implex Corp., the outcome of
the Department of Justice investigation announced in March 2005 and the pending informal Securities
and Exchange Commission investigation of Centerpulse AG accounting, control of costs and expenses,
the ability to form and implement alliances, changes in reimbursement programs by third-party
payors, governmental laws and regulations affecting our U.S. and international businesses,
including tax obligations and risks, product liability and intellectual property litigation losses,
international growth, general industry and market conditions and growth rates and general domestic
and international economic conditions including interest rate and currency exchange rate
fluctuations. Readers of this report are cautioned not to place undue reliance on these
forward-looking statements, since, while the Company believes the assumptions on which the
forward-looking statements are based are reasonable, there can be no assurance that these
forward-looking statements will prove to be accurate. This cautionary statement is applicable to
all forward-looking statements contained in this report.
Item 3. Quantitative and Qualitative Disclosures About Market Risk
There have been no material changes from the information provided in the Companys Annual
Report on Form 10-K for the year ended December 31, 2004.
34
Item 4. Controls and Procedures
The Company carried out an evaluation under the supervision and participation of the Companys
management, including the Chief Executive Officer and Chief Financial Officer, of the effectiveness
of the design and operation of the Companys disclosure controls and procedures. Based upon that
evaluation, the Companys management, including the Chief Executive Officer and Chief Financial
Officer, concluded that the Companys disclosure controls and procedures were effective as of June
30, 2005. There have been no changes in the Companys internal control over financial reporting
that occurred during the quarter ended June 30, 2005, that have materially affected, or are
reasonably likely to materially affect, the Companys internal control over financial reporting.
35
Part
II Other Information
Item 1. Legal Proceedings
Information pertaining to legal proceedings can be found in Note 12 to the interim
consolidated financial statements included in Part I of this report.
Item 4. Submission of Matters to a Vote of Security Holders
The annual meeting of the stockholders of the Company was held on May 2, 2005. The matters
submitted to the stockholders for a vote included:
|
|
|
the election of one director to the Board of Directors; |
|
|
|
|
the approval of a proposed amendment to the Zimmer Holdings, Inc. TeamShare Stock Option
Plan; |
|
|
|
|
ratification of the selection of PricewaterhouseCoopers LLP (PwC) as the Companys
independent registered public accounting firm for 2005; and |
|
|
|
|
a stockholder proposal relating to auditor independence. |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Number of |
|
|
|
|
|
|
|
|
|
|
|
|
Votes |
|
|
|
|
|
Number of |
|
|
Number of |
|
AGAINST or |
|
Number of |
|
BROKER |
Matter |
|
Votes FOR |
|
WITHHELD |
|
ABSTENTIONS |
|
NON-VOTES |
Election of J.
Raymond Elliott as
director |
|
|
205,735,936 |
|
|
|
6,649,885 |
|
|
|
0 |
|
|
|
0 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Amendment to the
Zimmer Holdings,
Inc. TeamShare
Stock Option Plan |
|
|
140,728,937 |
|
|
|
38,238,101 |
|
|
|
2,167,147 |
|
|
|
31,251,636 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Ratification of PwC
as the Companys
independent
registered public
accounting firm for
2005 |
|
|
209,465,193 |
|
|
|
1,420,560 |
|
|
|
1,500,068 |
|
|
|
0 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Stockholder
proposal relating
to auditor
independence |
|
|
20,114,668 |
|
|
|
158,343,582 |
|
|
|
2,675,935 |
|
|
|
31,251,636 |
|
Following are the directors, other than the director elected at the annual meeting, whose
terms of office as directors continued after the annual meeting: Stuart M. Essig, Larry C.
Glasscock, John L. McGoldrick and Augustus A. White, III, M.D., Ph.D.
Item 5. Other Information
During the period covered by this Quarterly Report on Form 10-Q, the Audit Committee of our
Board of Directors approved the engagement of PwC, the Companys independent registered
36
public
accounting firm, to perform certain non-audit services related to certain tax matters. This
disclosure is made pursuant to Section 10A(i)(2) of the Securities Exchange Act of 1934, as added
by Section 202 of the Sarbanes-Oxley Act of 2002.
Item 6. Exhibits
The following documents are filed as exhibits to this report:
|
|
|
10.1
|
|
Change in Control Severance Agreement with Cheryl R. Blanchard
|
|
|
|
10.2
|
|
Benefit Equalization Plan of Zimmer Holdings, Inc. and Its
Subsidiary or Affiliated Corporations Participating in the Zimmer Holdings, Inc. Savings and Investment Program
|
|
|
|
10.3
|
|
Benefit Equalization Plan of Zimmer Holdings, Inc. and Its
Subsidiary or Affiliated Corporations Participating in the
Zimmer Holdings, Inc. Retirement Income Plan or the Zimmer Puerto Rico Retirement Income Plan
|
|
|
|
10.4
|
|
First Amendment of Benefit Equalization Plan of Zimmer
Holdings, Inc. and Its Subsidiary or Affiliate Corporations
Participating in the Zimmer Holdings, Inc. Retirement Income Plan or the Zimmer Puerto Rico Retirement Income Plan
|
|
|
|
31.1
|
|
Certification pursuant to Rule 13a-14(a)/15d-14(a) of the
Securities Exchange Act of 1934 of the Chief Executive
Officer, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
|
|
|
|
31.2
|
|
Certification pursuant to Rule 13a-14(a)/15d-14(a) of the
Securities Exchange Act of 1934 of the Chief Financial
Officer, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
|
|
|
|
32
|
|
Certifications pursuant to 18
U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 |
37
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused
this report to be signed on its behalf by the undersigned thereunto duly authorized.
|
|
|
|
|
ZIMMER HOLDINGS, INC. |
|
|
|
|
|
(Registrant) |
|
|
|
Date: August 9, 2005
|
|
By: /s/ Sam R. Leno |
|
|
|
|
|
Sam R. Leno |
|
|
Executive Vice President, Corporate Finance |
|
|
and Operations and Chief Financial Officer |
|
|
|
Date: August 9, 2005
|
|
By: /s/ James T. Crines |
|
|
|
|
|
James T. Crines |
|
|
Senior Vice President, Finance/Controller |
|
|
and Information Technology |
38